Soleno Therapeutics INC Form 4 insider transactions

James H. Mackaness, CFO of Soleno Therapeutics Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Patricia C. Hirano, a Senior Vice President at Soleno Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Anish Bhatnagar, CEO of Soleno Therapeutics, sold shares of common stock on October 1, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Kristen Yen, a Senior Vice President at Soleno Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

James H. Mackaness, CFO of Soleno Therapeutics Inc., sold shares of common stock on August 28 and 29, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Patricia C. Hirano, a Senior Vice President at Soleno Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

CEO of Soleno Therapeutics, Anish Bhatnagar, reports selling shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Vivo Opportunity, LLC, a 10% owner of Soleno Therapeutics Inc, reports selling a significant number of shares over three days in August 2024.

Raymond W. Urbanski, Chief Development Officer of Soleno Therapeutics, acquired 145,000 stock options on August 13, 2024.

Director Bir Dawn Carter reports acquiring 13,000 shares of Soleno Therapeutics common stock through restricted stock units.

Kristen Yen, a Senior Vice President at Soleno Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

James Mackaness, CFO of Soleno Therapeutics, sold shares of the company's common stock on August 5th and 6th, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Patricia C. Hirano, a Senior Vice President at Soleno Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

CEO of Soleno Therapeutics, Anish Bhatnagar, sold shares of common stock between August 5th and August 6th, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, acquired 40,000 shares of common stock on July 17, 2024, through restricted stock units (RSUs).

Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics, reports acquiring 35,000 shares of common stock and disposing of an unspecified amount through restricted stock units.

Kristen Yen, a Senior Vice President at Soleno Therapeutics, reported acquiring 85,000 shares of common stock and disposing of other shares, according to a Form 4 filing with the SEC.

Patricia C Hirano, a Senior Vice President at Soleno Therapeutics, acquired 85,000 shares of common stock on July 17, 2024, in the form of restricted stock units (RSUs).

James H. Mackaness, CFO of Soleno Therapeutics, reports the acquisition of 100,000 shares of common stock through restricted stock units (RSUs).

Anish Bhatnagar, CEO of Soleno Therapeutics, reports acquiring 850,000 shares of common stock and disposing of shares, according to a Form 4 filing with the SEC.

Kristen Yen, Senior Vice President at Soleno Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

James H. Mackaness, CFO of Soleno Therapeutics Inc., sold shares of common stock on July 1, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Patricia C Hirano, Senior Vice President at Soleno Therapeutics, sold shares of common stock on July 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Anish Bhatnagar, CEO of Soleno Therapeutics, sold shares of common stock on July 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Director Birgitte Volck reported the acquisition of 6,500 shares of Soleno Therapeutics Inc. as restricted stock units (RSUs) on June 6, 2024.

Director Andrew Sinclair acquired 6,500 restricted stock units in Soleno Therapeutics Inc. on June 6, 2024.

Director Matthew Pauls acquired 6,500 shares of Soleno Therapeutics stock in the form of restricted stock units (RSUs) on June 6, 2024.

Director Mario Ernest reports acquiring 6,500 shares of Soleno Therapeutics common stock through restricted stock units.

William G. Harris, a director of Soleno Therapeutics Inc., acquired 6,500 restricted stock units on June 6, 2024.

Director Mario Ernest purchased 62,000 shares and warrants of Soleno Therapeutics at $4.50 per share, while also adjusting previously reported holdings.